Literature DB >> 11566035

Pathogenesis of NSAID-induced gastroduodenal mucosal injury.

J L Wallace1.   

Abstract

The use of non-steroidal anti-inflammatory drugs (NSAIDs), even in the era of selective COX-2 inhibitors, remains limited by the ability of these agents to cause gastroduodenal ulceration and bleeding. This damage is caused mainly through the ability of these agents to inhibit prostaglandin synthesis, which has a negative impact on several components of mucosal defence. Many NSAIDs also have topical irritant effects on the epithelium which may be particularly important in the production of small intestinal injury. While the presence of acid in the lumen of the stomach may not be a primary factor in the pathogenesis of NSAID-induced gastroenteropathy it can make an important contribution to the chronicity of these lesions and to bleeding by impairing the restitution process, interfering with haemostasis and inactivating several growth factors that are important in mucosal defence and repair. Through better understanding of the pathogenesis of ulcers induced by NSAIDs, some new approaches to the development of more effective and safer anti-inflammatory drugs have been taken in recent years. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566035     DOI: 10.1053/bega.2001.0229

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  35 in total

1.  Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage.

Authors:  Corrado Blandizzi; Matteo Fornai; Rocchina Colucci; Gianfranco Natale; Valter Lubrano; Cristina Vassalle; Luca Antonioli; Gloria Lazzeri; Mario Del Tacca
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

2.  Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage.

Authors:  M Fornai; G Natale; R Colucci; M Tuccori; G Carazzina; L Antonioli; S Baldi; V Lubrano; A Abramo; C Blandizzi; M Del Tacca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-08-04       Impact factor: 3.000

Review 3.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

4.  Aqueous suspension of anise "Pimpinella anisum" protects rats against chemically induced gastric ulcers.

Authors:  Ibrahim A Al Mofleh; Abdulqader A Alhaider; Jaber S Mossa; Mohammed O Al-Soohaibani; Syed Rafatullah
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

5.  Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.

Authors:  Mamoun M Alhamadsheh; Stephen Connelly; Ahryon Cho; Natàlia Reixach; Evan T Powers; Dorothy W Pan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef
Journal:  Sci Transl Med       Date:  2011-08-24       Impact factor: 17.956

6.  MAGL inhibition modulates gastric secretion and motility following NSAID exposure in mice.

Authors:  Molly S Crowe; Steven G Kinsey
Journal:  Eur J Pharmacol       Date:  2017-05-03       Impact factor: 4.432

7.  AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.

Authors:  Sravan C Penchala; Stephen Connelly; Yu Wang; Miki S Park; Lei Zhao; Aleksandra Baranczak; Irit Rappley; Hannes Vogel; Michaela Liedtke; Ronald M Witteles; Evan T Powers; Natàlia Reixach; William K Chan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef; Mamoun M Alhamadsheh
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

8.  Evaluation of mucosal damage and recovery in the gastrointestinal tract of rats by a penetration enhancer.

Authors:  Yogeeta Narkar; Ronald Burnette; Reiner Bleher; Ralph Albrecht; Angki Kandela; Joseph R Robinson
Journal:  Pharm Res       Date:  2007-12-27       Impact factor: 4.200

9.  Diflunisal for ATTR cardiac amyloidosis.

Authors:  Adam Castaño; Stephen Helmke; Julissa Alvarez; Susan Delisle; Mathew S Maurer
Journal:  Congest Heart Fail       Date:  2012-07-02

10.  Antagonism of thromboxane receptors by diclofenac and lumiracoxib.

Authors:  E Selg; C Buccellati; M Andersson; G E Rovati; M Ezinga; A Sala; A-K Larsson; M Ambrosio; E Ambrosio; L Låstbom; V Capra; B Dahlén; A Ryrfeldt; G C Folco; S-E Dahlén
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.